December 21, 2007
Endocyte Announces License Agreement with R&D Biopharmaceuticals for the Development of Targeted Tubulysin Chemotherapeutic Agents
December 20, 2007
Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801
December 19, 2007
LineaGen Announces $5.8 Million Series A Financing
December 18, 2007
Pacira Pharmaceuticals Names David M. Stack CEO & President
December 17, 2007
Chandra Lovejoy joins Endocyte as Director of Regulatory Affairs
December 13, 2007
Naviscan’s PEM Flex™ Scanner Shows Promising New Data in Breast Cancer Management
December 11, 2007
Chimerix Initiates a Multi-dose Clinical Trial of the Company’s Lead Compound, CMX001, for the Treatment for Smallpox Infection
December 10, 2007
CalciMedica: CRACking toxicity
December 05, 2007
Theregen Completes Enrollment of Anginera Phase I Safety Trial; Prepares for Phase II Submission
November 27, 2007
Gemin X Announces Publication of Unique Mechanism of Action of Obatoclax in Proceedings of the National Academy of Sciences
November 26, 2007
Novocell Company Profile & History
November 07, 2007
Gemin X To Present at BIO-Europe 2007 -- Corporate Overview Includes Targeted Cancer Programs in Development, Obatoclax and GMX 1777
October 25, 2007
Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors
October 24, 2007
Gemin X Identifies Molecules that Inhibit Telomere Maintenance Proteins Important to Cancer Cell Survival
October 24, 2007
Gemin X Presents Mechanism of Action of GMX1778 and Preclinical Data of its Prodrug GMX1777
October 22, 2007
Orphan Australia Receives Depodur Approval
October 19, 2007
Xytis Names Gordon H. Busenbark as Chief Financial Officer
October 16, 2007
Tomophase To Exhibit First Cross-Sectional Images of Human Bronchus Using Proprietary OCT System
October 15, 2007
A Novel Near-Infrared Spectroscopy System to Characterize Coronary Plaques Will Be Featured at TCT 2007
October 01, 2007
Gemin X Pharmaceuticals, Inc. Appoints Eric Roberts to Board of Directors
September 27, 2007
Flynn Pharma Acquires Rights from Pacira Pharmaceuticals to DepoDur, the Only Extended-Release Epidural Opioid for Pos-Operative Pain, in Europe
September 20, 2007
JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
August 30, 2007
Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways with Proliferation and Self-Renewal of Human Embryonic Stem Cells
August 17, 2007
CardioNet files with US SEC for $150 million IPO
August 13, 2007
Taligen: De-amplifying complement
August 09, 2007
WilsonRx® Survey Reports 7 Out of 10 Customers of Leading Retail Chain Pharmacies are Interested in Prescription Pickup Kiosks.
July 24, 2007
Theregen Launches Second Phase I Study
July 19, 2007
Naviscan PET Systems Appoints Paul J. Mirabella as President and CEO
July 16, 2007
Series C to Support Continued Development of Stem Cell Therapy
July 10, 2007
Cylene Pharmaceuticals Appoints David M. Ryckman, Ph.D. as Vice President of Manufacturing and Pharmaceutical Operations
June 28, 2007
Cylene Pharmaceuticals’ Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
June 25, 2007
Cylene's 2007 ASCO Poster -- Phase I Clinical Trial of CX-3543, a Pro-Apoptotic Antitumor Agent
June 18, 2007
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for its Disease-Modifying Alzheimer’s Therapy
June 6, 2007
CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President
May 03, 2007
Naviscan PET Systems Completes $15 Million Series C Financing
April 23, 2007
Arrhythmia Detection and Alarm Consortium Established
April 10, 2007
CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
March 23, 2007
Endocyte Secures $15 Million in Series C-3 Round of Financing
March 20, 2007
Chimerix Presents at C21 BioVentures Conference
March 14, 2007
Artielle Immunotherapeutics Initiates Clinical Trials For Multiple Sclerosis
March 13, 2007
Xytis Enrolls First Patient in Phase II Clinical Study with Anatibant (XY2405) for Traumatic Brain Injury “Brain Trail”
March 06, 2007
Chimerix Presents at Bio-Europe Spring 2007 Conference
February 23, 2007
Chimerix Raises $23.1 Million to Advance Antiviral Drug Pipeline
February 20, 2007
Athenagen Announces Name Change to CoMentis
January 31, 2007
Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study
January 31, 2007
Gemin X Initiates Phase 1/2 Combination Trials with GX15-070 in Non-Small Cell Lung Cancer and Mantle Cell Lymphoma
January 23, 2007
Cylene Pharmaceuticals Closes $44 Million Series C Financing
January 7, 2007
Xytis Begins Phase II Clinical Study
January 7, 2007
Xytis Announces $40 Million Grant from NIH